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Abstract—Cancer diagnosis, prognosis, and therapeutic re-
sponse predictions are based on morphological information
from histology slides and molecular profiles from genomic data.
However, most deep learning-based objective outcome prediction
and grading paradigms are based on histology or genomics
alone and do not make use of the complementary information
in an intuitive manner. In this work, we propose Pathomic
Fusion, an interpretable strategy for end-to-end multimodal
fusion of histology image and genomic (mutations, CNV, RNA-
Seq) features for survival outcome prediction. Our approach
models pairwise feature interactions across modalities by taking
the Kronecker product of unimodal feature representations, and
controls the expressiveness of each representation via a gating-
based attention mechanism. Following supervised learning, we
are able to interpret and saliently localize features across each
modality, and understand how feature importance shifts when
conditioning on multimodal input. We validate our approach
using glioma and clear cell renal cell carcinoma datasets from
the Cancer Genome Atlas (TCGA), which contains paired whole-
slide image, genotype, and transcriptome data with ground truth
survival and histologic grade labels. In a 15-fold cross-validation,
our results demonstrate that the proposed multimodal fusion
paradigm improves prognostic determinations from ground truth
grading and molecular subtyping, as well as unimodal deep
networks trained on histology and genomic data alone. The
proposed method establishes insight and theory on how to
train deep networks on multimodal biomedical data in an
intuitive manner, which will be useful for other problems in
medicine that seek to combine heterogeneous data streams for
understanding diseases and predicting response and resistance
to treatment. Code and trained models are made available at:
https://github.com/mahmoodlab/PathomicFusion.
Index Terms—Multimodal Learning, Graph Convolutional Net-
works, Survival Analysis
I. INTRODUCTION
CANCER diagnosis, prognosis and therapeutic responseprediction is usually accomplished using heterogeneous
data sources including histology slides, molecular profiles, as
well as clinical data such as the patient’s age and comorbidities.
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Histology-based subjective and qualitative analysis of the tumor
microenvironment coupled with quantitative examination of
genomic assays is the standard-of-care for most cancers in
modern clinical settings [1]–[4]. As the field of anatomic
pathology migrates from glass slides to digitized whole slide
images, there is a critical opportunity for development of
algorithmic approaches for joint image-omic assays that make
use of phenotypic and genotypic information in an integrative
manner.
The tumor microenvironment is a complex milieu of cells that
is not limited to only cancer cells, as it also contains immune,
stromal, and healthy cells. Though histologic analysis of tissue
provides important spatial and morphological information of
the tumor microenvironment, the qualitative inspection by
human pathologists has been shown to suffer from large
inter- and intraobserver variability [5]. Moreover, subjective
interpretation of histology slides does not make use of the
rich phenotypic information that has shown to have prognostic
relevance [6]. Genomic analysis of tissue biopsies can provide
quantitative information on genomic expression and alterations,
but cannot precisely isolate tumor-induced genotypic measures
and changes from those of non-tumor entities such as normal
cells. Current modern sequencing technologies such as single
cell sequencing are able to resolve genomic information of
individual cells in tumor specimens, with spatial transcriptomics
and multiplexed immunofluoresence able to spatially resolve
histology tissue and genomics together [7]–[12]. However, these
technologies currently lack clinical penetration.
Oncologists often rely on both the qualitative information
from histology and quantitative information from genomic data
to predict clinical outcomes [13], however, most histology
analysis paradigms do not incorporate genomic information.
Moreover, such methods often do not explicitly incorporate
information from the spatial organization and community
structure of cells, which have known diagnostic and prognostic
relevance [6], [14]–[16]. Fusing morphological information
from histology and molecular information from genomics
provides an exciting possibility to better quantify the tumor mi-
croenvironment and harness deep learning for the development
of image-omic assays for early diagnosis, prognosis, patient
stratification, survival, therapeutic response and resistance
prediction.
Contributions: The contributions of this paper are high-
lighted as follows:
• Novel Multimodal Fusion Strategy: We propose Path-
ar
X
iv
:1
91
2.
08
93
7v
3 
 [c
s.C
V]
  3
 Se
p 2
02
0
2Fig. 1: Pathomic Fusion: An integrated framework for multimodal fusion of histology and genomic features for survival outcome
prediction and classification. Histology features may be extracted using CNNs, parameter efficient GCNs or a combination of
the two. Unimodal networks for the respective image and genomic features are first trained individually for the corresponding
supervised learning task, and then used as feature extractors for multimodal fusion. Multimodal fusion is performed by applying
an gating-based attention mechanism to first control the expressiveness of each modality, followed by the Kronecker product to
model pairwise feature interactions across modalities.
omic Fusion, a novel framework for multimodal fusion
of histology and genomic features (Fig. 1). Our proposed
method models pairwise feature interactions across modal-
ities by taking the Kronecker product of gated feature
representations, and controls the expressiveness of each
representation using a gating-based attention mechanism.
• GCNs for Cancer Outcome Prediction: We present
a novel approach for learning cell graph features in
histopathology tissue using graph convolutional networks
(Fig. 2), and present the first application of GCNs
for cancer survival outcome prediction from histology.
GCNs act as a complementary method to CNNs for
morphological feature extraction, and may be used in
ileu of or in combination with CNNs during multimodal
fusion for fine-grained patient stratification.
• Objective Image-Omic Quantitative Study with Mul-
timodal Interpretability: In a rigorous 15-fold cross-
validation-based analysis on two different disease models,
we demonstrate that our image-omic fusion paradigm
outperforms subjective prognostic determinations that
use grading and subtyping, as well as previous state-
of-the-art results for patient stratification that use deep
learning. To interpret predictions made by our network in
survival analysis, we use both class-activation maps and
gradient-based attribution techniques to distill prognostic
morphological and genomic features.
II. RELATED WORK
Survival Analysis for Cancer Outcome Prediction: Cancer
prognosis via survival outcome prediction is a standard method
used for biomarker discovery, stratification of patients into
distinct treatment groups, and therapeutic response prediction
[17]. With the availability of high-throughput data from next-
generation sequencing, statistical survival models have become
one of the mainstay approaches for performing retrospective
studies in patient cohorts with known cancer outcomes, with
common covariates including copy number variation (CNV),
mutation status, and RNA sequencing (RNA-Seq) expression
[17], [18]. Recent work has incorporated deep learning into
survival analysis, in which the covariates for a Cox model are
learned using a series of fully connected layers. Yousefi et al.
[19] proposed using stacked denoising autoencoders to learn
a low dimension representation of RNA-Seq data for survival
analysis, and in a follow-up work [19], they used Feedforward
Networks to examine the relationship between gene signatures
and survival outcomes. Huang et al. [20] proposed using
weighted gene-expression network analysis as another approach
for dimensionality reduction and learning eigen-features from
RNA-Seq and micro-RNA data for survival analysis in TCGA.
However, these approaches do not incorporate the wealth
of multimodal information from heterogeneous data sources
including diagnostic slides, which may capture the inherent
phenotypic tumor heterogeneity that has known prognostic
value.
Multimodal Deep Learning: Multimodal fusion via deep
3learning has emerged as an interdisciplinary field that seeks to
correlate and combine disparate heterogeneous data modalities
to solve difficult prediction tasks in areas such as visual percep-
tion, human-computer interaction, and biomedical informatics
[21]. Depending on the problem, approaches for multimodal
fusion range from fusion of multiview data of the same
modality, such as the collection of RGB, depth and infrared
measurements for visual scene understanding, to the fusion
of heterogeneous data modalities, such as integrating chest
X-rays, textual clinical notes, and longitudinal measurements
for intensive care monitoring [22]. In the natural language
processing community, Kim et al. [23] proposed a low-
rank feature fusion approach via the Hadamard product for
visual question answering, often referred to as as bilinear
pooling. Zadeh et al. [24] studied feature fusion via the
Kronecker product for sentiment analysis in audio-visual speech
recognition.
Multimodal Fusion of Histology and Genomics: Though
many multimodal fusion strategies have been proposed to
address the unique challenges in computer vision and natural
language processing, strategies for fusing data in the biomedical
domain (e.g. histology images, molecular profiles) are relatively
unexplored. In cancer genomics, most works have focused
on establishing correspondences between histology tissue and
genomics [25]–[28]. For solving supervised learning tasks,
previous works have generally relied on the ensembling of
extracted feature embeddings from separately trained deep
networks (termed late fusion) [20], [29], [30]. Morbadersany
et al. [29] proposed a strategy for combining histology image
and genomic features via vector concatenation. Cheerla et al.
[31] developed an unsupervised multimodal encoder network
for integrating histology image and genomic modalities via
concatenation that is resilient to missing data. Shao et al. [32]
proposed an ordinal multi-modal feature selection approach that
identifies important features from both pathological images and
multi-modal genomic data, but relies on handcrafted features
from cell graph features in histology images. Beyond late
fusion, there is limited work in deep learning-based multimodal
learning approaches that combine histology and genomic data.
Moreover, there is little work made in interpreting histology
features in these multimodal deep networks.
Graph-based Histology Analysis: Though CNNs have
achieved remarkable performance in histology image classifica-
tion and feature representation, graph-based histology analysis
has become a promising alternative that rivals many competitive
benchmarks. The motivation for interpreting histology images
as a graph of cell features (cell graph) is that these computa-
tional morphological (morphometric) features are more easily
computed, and explicitly capture cell-to-cell interactions and
their spatial organization with respect to the tissue. Prior to deep
learning, previous works in learning morphological features
from histology images have relied on manually constructed
graphs and computing predefined statistics [33]. Doyle et al.
[34] was the first work to approach Gleason score grading in
prostate cancer using Voronoi and Delauney tessellations. Shao
et al. [32] presented an interesting approach for feature fusion
of graph and molecular profile features, with graph features
constructed manually and fused via vector concatenation similar
to Huang et al. [20]. Motivated by the success of representation
learning in graphs using deep networks [35]–[38], Anand et
al. [15], Zhou et al., [39] and Wang et al. [16] have used
graph convolutional networks for breast, colon and prostate
cancer histology classification respectively. Currently, however,
there have been no deep learning based-approaches that have
used graph convolutional networks for for survival outcome
prediction.
III. METHODS
Given paired histology and genomic data with known
cancer outcomes, our objective is to learn a robust multimodal
representation from both modalities that would outperform
unimodal representations in supervised learning. Previous
works have only relied on CNNs for extracting features from
histology images, and late fusion for integrating image features
from CNNs with genomic features. In this section, we present
our novel approach for integrating histology and genomic data,
Pathomic Fusion, which fuses histology image, cell graph,
and genomic features into a multimodal tensor that explicitly
models bimodal and trimodal interactions from each modality.
In Pathomic Fusion, histology features are extracted as two
different views: image-based features using Convolutional
Neural Networks (CNNs), and graph-based features using
Graph Convolutional Networks (GCNs). Both networks would
extract similar morphological features, however, cell graphs
from histology images are a more explicit feature representation
that directly model cell-to-cell interactions and cell community
structure. Following the construction of unimodal features,
we propose a gating-based attention mechanism that controls
the expressiveness of each feature before constructing the
multimodal tensor. The objective of the multimodal tensor
is to capture the space of all possible interactions between
features across all modalities, with the gating-based attention
mechanism used to regularize unimportant features. In sub-
sections A-C, we describe our approach for representation
learning in each modality, with subsections D-E describing our
multimodal learning paradigm and approach for interpretability.
Additional implementation and training details are found in
Appendix B.
A. Learning Patient Outcomes from H&E Histology Tissue
Images using Convolutional Neural Networks
Anatomic pathology has the ability to reveal the inherent
phenotypic intratumoral heterogeneity of cancer, and has been
an important tool in cancer prognosis for the past century [40]–
[43]. Tumor microenvironment features such as high cellularity
and microvascular proliferation have been extensively linked
to tumor suppressor deficiency genes and angiogenesis, and
recognized to have clinical implications in the recurrence and
proliferation of cancer [44]. To capture these features, we train
a Convolutional Neural Network (CNN) on 512× 512 image
regions-of-interest (ROIs) at 20× magnification (0.5 µm/pixel)
as representative regions of cancer pathology. The network
architecture of our CNN is VGG19 with batch normalization,
which we finetuned using pre-existing weights trained on
ImageNet. We extract a hi ∈ R32×1 embedding from the
last hidden layer of our Histology CNN, which we use as
4Fig. 2: Graph Convolutional Network for learning morphometric cell features from histology images. We represent cells in
histology tissue as nodes in a graph, where cells are isolated using a deep learning-based nuclei segmentation algorithm and the
connections between cells are made using KNN. Features for each cell are initialized using handcrafted features as well as deep
features learned using contrastive predictive coding. The aggregate and combine functions are adopted from the GraphSAGE
architecture, with the node masking and hierarchical pooling strategy adopted from SAGEPool.
input into Pathomic Fusion. This network is supervised by the
Cox partial likelihood loss for survival outcome prediction,
and cross entropy loss for grade classification (Supplement,
Appendix A).
B. Learning Morphometric Cell and Graph Features using
Graph Convolutional Networks
The spatial heterogeneity of cells in histopathology has
potential in informing the invasion and progression of cancer
and in bioinformatics tasks of interest such as cancer subtyping,
biomarker discovery and survival outcome prediction [40], [45].
Unlike image-based feature representation of histology tissue
using CNNs, cell graph representations explicitly capture only
pre-selected features of cells, which can be scaled to cover
larger regions of histology tissue.
Let G = (V,E) denote a graph with nodes V and edges
E. We define X ∈ RN×F as a feature matrix of N nodes
in V with F -dimensional features, and A ∈ RN×N as the
adjacency matrix that holds the graph topology. To construct
graphs that would capture the tumor microenvironment (Fig 2),
on the same histology ROI used as input to our CNN, we 1):
perform semantic segmentation to detect and spatially localize
cells in a histopathology region-of-interest to define our set
of nodes V , 2): use K-Nearest Neighbors to find connections
between adjacent cells to define our set of edges E, 3): calculate
handcrafted and deep features for each cell that would define
our feature matrix X , and 4): use graph convolutional networks
to learn a robust representation of our entire graph for survival
outcome prediction.
Nuclei Segmentation: Accurate nuclei segmentation is impor-
tant in defining abnormal cell features such as nuclear atypia,
abundant tumor cellularity, and other features that would be
indicative of cancer progression [46]–[49]. Previous works rely
on conventional fully convolutional networks that minimize a
pixel-wise loss [50], which can cause the network to segment
multiple nuclei as one, leading to inaccurate feature extraction
of nuclei shape and community structure. To overcome this
issue, we use the same conditional generative adversarial
network (cGAN) from our previous work to learn an appropriate
loss function for semantic segmentation, which circumvents
manually engineered loss functions [51]–[53]. As described in
our previous work [51], the conditional GAN framework con-
sists of two networks (a generator G and a discriminator D) that
compete against each other in a min-max game to respectively
minimize and maximize the objective minGmaxD L(G,D).
Specifically, G is a segmentation network that learns to translate
histology tissue images n into realistic segmentation masks m,
and D is a binary classification network that aims to distinguish
real and predicted pairs of tissue ((n,m) vs. (n, S(n)). Our
generator is supervised with a L1 loss and adversarial loss
function, in which the adversarial loss penalizes the generator
for producing segmentation masks that are unrealistic.
LGAN (S,DM ) =Em,n∼pdata(m,n) [logDM (m,n)]
+En∼pdata(n) [log (1−DM (m,S(n)))]
Cell Graph Construction: From our segmented nuclei, we
use the K-Nearest Neighbors (KNN) algorithm from the Fast
Library for Approximate Nearest Neighbours (FLANN) library
to construct the edge set and adjacency matrix of our graph [54]
(Fig 2). We hypothesize that adjacent cells will have the most
significant cell-cell interactions and limit the adjacency matrix
to K nearest neighbours. In our investigations, we used K = 5
5to detect community structure and model cellular interactions.
Using KNN, our adjacency matrix A is defined as:
Aij
{
1 if j ∈ KNN(i) and D(i, j) < d
0 otherwise
Manual Cell Feature Extraction: For each cell, we com-
puted eight contour features (major axis length, minor axis
length, angular orientation, eccentricity, roundness, area, and
solidity), as well as four texture features from gray-level
co-occurence matrices (GLCM) (dissimilarity, homogeneity,
angular second moment, and energy). Contours were obtained
from segmentation results in nuclei segmentation, and GLCMs
were calculated from 64× 64 image crops centered over each
contour centroid. These twelve features were selected for
inclusion in our feature matrix X , as they would describe
abnormal morphological features about glioma cells such as
atypia, nuclear pleomorphism, and hyperchromatism.
Unsupervised Cell Feature Extraction using Contrastive
Predictive Coding: Besides manually computed statistics, we
also used an unsupervised technique known as contrastive
predictive coding (CPC) [55]–[57] to extract 1024-dimensional
features from tissue regions of size 64 × 64 centered around
each cell in a spatial graph. Given a high-dimensional data
sequence {xt} (256 × 256 image crop from the histology
ROI), CPC is designed to capture high-level representations
shared among different portions (64 × 64 image patches) of
the complete signal. The encoder network genc transforms
each data observation xi into a low-dimensional representation
zi and learns via a contrastive loss whose optimization leads
to maximizing the mutual information between the available
context ct, computed from a known portion of the encoded
sequence {zi}, i ≤ t and future observations zt+k, k > 0. By
minimizing the CPC objective, we are able to learn rich feature
representations shared among various tissue regions that are
specific to the cells in the underlying tissue site. Examples
include the morphology and distinct arrangement of different
cell types, inter-cellular interactions, and the microvascular
patterns surrounding each cell. To create CPC features for
each cell, we encode 64× 64 image patches centered over the
centroid of each cell. These features are concatenated with our
handcrafted features during cell graph construction.
Graph Convolutional Network: Similar to CNNs, GCNs
learn abstracts feature representations for each feature in a
node via message passing, in which nodes iteratively aggregate
feature vectors from their neighborhood to compute a new
feature vector at the next hidden layer in the network [38].
The representation of an entire graph can be obtained through
pooling over all the nodes, which can then be used as input for
tasks such as classification or survival outcome prediction. Such
convolution and pooling operations can defined as follows:
a(k)v = AGGREGATE
(k)
({
h(k−1)u : u ∈ N (v)
})
h(k)v = COMBINE
(k)
(
h(k−1)v , a
(k)
v
)
where h(k)v is the feature vector of node v at the k − 1-th
iteration of the neighborhood aggregation, a(k)v is the feature
vector of node v at the next iteration, and AGGREGATE and
COMBINE are functions for combining feature vectors between
hidden layers. As defined in Hamilton et al., we adopt the
AGGREGATE and COMBINE definitions from GraphSAGE
[35], which for a given node, represents the next node hidden
layer as the concatenation of the current hidden layer with the
neighborhood features:
a(k)v = MAX
({
ReLU
(
W · h(k−1)u
)
,∀u ∈ N (v)
})
h(k)v =W ·
[
h(k−1)v , a
(k)
v
]
Unlike other graph-structured data, cell graphs exhibit a
hierarchical topology, in which the degree of eccentricity and
clustered components of nodes in a graph define multiple views
of how cells are organized in the tumor micro-environment:
from fine-grained views such as local cell-to-cell interactions, to
coarser-grained views such as structural regions of cell invasion
and metastasis. In order to encode the hierarchical structure
of cell graphs, we adopt the self-attention pooling strategy
SAGPOOL presented in Lee et al. [36], which is a hierarchical
pooling method that performs local pooling operations of node
embeddings in a graph. In attention pooling, the contribution
of each node embedding in the pooling receptive field to the
next network layer is adaptively learned using an attention
mechanism. The attention score Z ∈ RN×1 for nodes in G
can be calculated as such:
Z = σ
(
SAGEConv
(
X,A+A2
))
where X are the node features, A is the adjacency matrix,
and SAGEConv is the convolution operator from GraphSAGE.
To also aggregate information from multiple scales in the
nuclei graph topology, we also adopt the hierarchical pooling
strategy in Lee et al. [36]. Since we are constructing cell
graphs on the entire image, no patch averaging of predicted
hazards needs to be performed. At the last hidden layer of
our Graph Convolutional SNN, we pool the node features into
a hg ∈ R32×1 feature vector, which we use as an input to
Pathomic Fusion.
C. Predicting Patient Outcomes from Molecular Profiles using
Self-Normalizing Networks
Advances in next-generation sequencing data have allowed
for the profiling of transcript abundance (RNA-Seq), copy
number variation (CNV), mutation status, and other molecular
characterizations at the gene level, and have been frequently
used to study survival outcomes in cancer. For example,
isocitrate dehydrogenase 1 (IDH1) is a gene that is important
for cellular metabolism, epigenetic regulation and DNA repair,
with its mutation associated with prolonged patient survival
in cancers such as glioma. Other genes include EGFR, VEGF
and MGMT, which are implicated in angiogenesis, which is
the process of blood vessel formulation that also allows cancer
to proliferate to other areas of tissue.
For learning scenarios that have hundreds to thousands of
features with relatively few training samples, Feedforward
networks are prone to overfitting. Compared to other kinds of
neural network architectures such as CNNs, weights in Feed-
forward networks are shared and thus more sensitive training
instabilities from perturbation and regularization techniques
6Fig. 3: Pathomic Fusion Applied to Glioblastoma and Lower Grade Glioma. A. Glioma hazard distributions amongst
shorter vs. longer surviving uncensored patients and molecular subtypes for Histology CNN and Pathomic Fusion. Patients
are defined as shorter surviving if patient death is observed before 5 years of the first follow-up (shaded red), and longer
surviving if patient death is observed after 5 years of the first follow-up (shaded blue). Pathomic Fusion predicts hazard in
more concentrated clusters than Histology CNN, while the distribution of hazard predictions from Histology CNN have longer
tails and are more varied across molecular subtypes. In analyzing the types of glioma in the three high density regions revealed
from Pathomic Fusion, we see that these regions corroborate with the WHO paradigm for stratifying patients into IDHwt ATC,
IDHmut ATC, and ODG (Appendix C, Table IV). B. Kaplan-Meier comparative analysis of using grade, molecular subtype,
Histology CNN and Pathomic Fusion in stratifying patient outcomes. Hazard predictions from Pathomic Fusion show better
stratification of mid-to-high risk patients than Histology CNN, and low-to-mid risk patients than molecular subtyping, which
follows the WHO paradigm. Low / intermediate / high risk are defined by the 33-66-100 percentile of hazard predictions.
Overlayed Kaplan-Meier estimates of our network predictions with WHO Grading is shown in the supplement (Appendix C,
Fig. 9).
such as stochastic gradient descent and Dropout. To mitigate
overfitting on high-dimensional low sample size genomics data
and employ more robust regularization techniques when training
Feedforward networks, we adopt the normalization layers from
Self-Normalizing Networks in Klambaeur et al. [58]. In Self-
Normalizing Networks (SNN), rectified linear unit (ReLU)
activations are replaced with scaled exponential linear units
(SeLU) to drive outputs after every layer towards zero mean
and unit variance. Combined with a modified regularization
technique (Alpha Dropout) that maintains this self-normalizing
property, we are able to train well-regularized Feedforward
networks that would be otherwise prone to instabilities as
a result of vanishing or explosive gradients. Our network
architecture consists of four fully-connected layers followed by
Exponential Linear Unit (ELU) activation and Alpha Dropout to
ensure the self-normalization property. The last fully-connected
layer is used to learn a representation hn ∈ R32×1, which is
used as input into our Pathomic Fusion (Fig. 1).
7Fig. 4: Pathomic Fusion Applied to Clear Cell Renal Cell Carcinoma. CCRCC hazard distributions amongst shorter vs.
longer surviving uncensored patients for Histology CNN and Pathomic Fusion. Patients are defined as shorter surviving if
patient death is observed before 3.5 years of the first follow-up (shaded red), and longer surviving if patient death is observed
after 3.5 years of the first follow-up (shaded blue). Pathomic Fusion was observed to able to stratify longer and shorter surviving
patients better than Histology CNN, exhibiting a bimodal distribution in hazard prediction. Overlayed Kaplan-Meier estimates
of our network predictions with WHO Grading is shown in the supplement (Appendix C, Fig. 10).
D. Multimodal Tensor Fusion via Kronecker Product and
Gating-Based Attention
For multimodal data in cancer pathology, there exists a data
heterogeneity gap in combining histology and genomic input
- histology images are spatial distributed as (R, G, B) pixels
in a two-dimensional grid, whereas cell graphs are defined
as a set of nodes V with different sized neighborhoods and
edges V , and genomic data is often represented as a one-
dimensional vector of covariates [30]. Our motivation for
multimodal learning is that the inter-modality interactions
between histology and genomic features would be able to
improve patient stratification into subtypes and treatment
groups. For example, in the refinement of histogenesis of
glioma, though morphological characteristics alone do not
correlate well with patient outcomes, their semantic importance
in drawing decision boundaries is changed when conditioned
on genomic biomarkers such as IDH1 mutation status and
chromosomal 1p19q arm codeletion [59].
In this work, we aim to explicitly capture these important
interactions using the Kronecker Product, which model feature
interactions across unimodal feature representations, that would
otherwise not be explicitly captured in feedforward layers.
Following the construction of the three unimodal feature repre-
sentations in the previous subsections, we build a multimodal
representation using the Kronecker product of the histology
image, cell graph, and genomic features (hi,hg,hn). The
joint multimodal tensor computed by the matrix outer product
of these feature vectors would capture important unimodal,
bimodal and trimodal interactions of all features of these three
modalities, shown in Fig. 1 and in the equation below:
hfusion =
[
hi
1
]
⊗
[
hg
1
]
⊗
[
hn
1
]
where ⊗ is the outer product, and hfusion is a differential
multimodal tensor that forms in a 3D Cartesian space. In
this computation, every neuron in the last hidden layer in the
CNN is multiplied by every other neuron in the last hidden
layer of the SNN, and subsequently multiplied with every
other neuron in the last hidden layer of the GCN. To preserve
unimodal and bimodal feature interactions when computing the
trimodal interactions, we append 1 to each unimodal feature
representation. For feature vectors of size [33×1], [33×1] and
[33×1], the calculated multimodal tensor would have dimension
[33× 33× 33], where the unimodal features (hi,hg,hn) and
bimodal feature interactions (hi ⊗ hg,hg ⊗ hn,hi ⊗ hn) are
defined along the outer dimension of the 3D tensor, and
the trimodal interactions (captured as hi ⊗ hg ⊗ hn) in the
inner dimension of the 3D tensor (Fig. 1). Following the
computation of this joint representation, we learn a final
network using fully-connected layers using the multimodal
tensor as input, supervised with the previously defined Cox
objective for survival outcome prediction and cross-entropy
8loss for grade classification. Ultimately, the value of Pathomic
Fusion is fusing heterogeneous modalities that have disparate
structural dependencies. Our multimodal network is initialized
with pretrained weights from the unimodal networks, followed
by end-to-end fine-tuning of the Histology GCN and Genomic
SNN.
To decrease the impact of noisy unimodal features during
multimodal training, before the Kronecker Product, we em-
ployed a gating-based attention mechanism that controls the
expressiveness of features of each modality [60]. In fusing
histology image, cell graph, and genomic features, some of
the captured features may have high collinearity, in which
employing a gating mechanism can reduce the size of the
feature space before computing the Kronecker Product. For
a modality m with a unimodal feature representation hm, we
learn a linear transformation Wign→m of modalities hi,hg,hn
that would score the relative importance of each feature in m,
denoted as zm in the equation below.
hm,gated = zm ∗ hm,∀m ∈ {i, g, n}
where, hm = ReLU(Wm · hm)
zm = σ(Wign→m · [hi,hg,hn])
zm can be interpreted as an attention weight vector, in
which modalities i, g, n attend over each feature in modality
m. Wm and Wign→m are weight matrix parameters we learn
for feature gating. After taking the softmax probability, we
take the element-wise product of features hm and scores zm
to calculate the gated representation.
E. Multimodal Interpretability
To interpret our network, we modified both Grad-CAM and
Integrated Gradients for visualizing image saliency feature
importance across multiple types of input. Grad-CAM is a
gradient-based localization technique used to produce visual
explanations in image classification, in which neurons whose
gradients have positive influence on a class of interest are used
to produce a coarse heatmap [61]. Since the last layer of our
network is a single neuron for outputting hazard, we modified
the target to perform back-propagation on the single neuron. As
a result, the visual explanations from our network correspond
with image regions used in predicting hazard (values ranging
from [-3,3]). For Histology GCN and Genomic SNN, we used
Integrated Gradients (IG), a gradient-based feature attribution
method that attributes the prediction of deep networks to their
inputs [62]. Similar to previous attribution-based methods such
as Layer-wise Relevance Propagation [63], IG calculates the
gradients of the input tensor x across different scales against
a baseline xi (zero-scaled), and then uses the Gauss-Legendre
quadrature to approximate the integral of gradients.
IGi(x) ::= (xi − x′i)×
∫ 1
α=0
∂F (x′ + α× (x− x′))
∂xi
dα
To adapt IG to graph-based structures, we treat the nodes in
our graph input as the batch dimension, and scale each node
in the graph by the number of integral approximation steps.
With multimodal inputs, we can approximate the integral of
gradients for each data modality.
IV. EXPERIMENTAL SETUP
A. Data Description
To validate our proposed multimodal paradigm for integrating
histology and genomic features, we collected glioma and
clear cell renal cell carcinoma data from the TCGA, a cancer
data consortium that contains paired high-throughput genome
analysis and diagnostic whole slide images with ground-truth
survival outcome and histologic grade labels. For astrocytomas
and glioblastomas in the merged TCGA-GBM and TCGA-LGG
(TCGA-GBMLGG) project, we used 1024× 1024 region-of-
interests (ROIs) from diagnostic slides curated by [29], and
used sparse stain normalization [64] to match all images to
a standard H&E histology image. Multiple region-of-interests
(ROIs) from diagnostic slides were obtained for some patients,
creating a total of 1505 images for 769 patients. 320 genomic
features from CNV (79), mutation status (1), and bulk RNA-
Seq expression from the top 240 differentially expressed genes
(240) were curated from the TCGA and the cBioPortal [65]
for each patient. For clear cell renal cell carcinoma in the
TCGA-KIRC project we used manually extracted 512× 512
ROIs from diagnostic whole slide images. For 417 patients
in CCRCC, we collected 3 512× 512 40x ROIs per patient,
yielding 1251 images total that were similarly normalized with
stain normalization. We paired these images with 357 genomic
features from CNV of genes with alteration frequency greater
than 7% (117) and RNA-Seq from the top 240 differentially
expressed genes (240). It should be noted that for TCGA-
GBMLGG had approximately 40% of the patients had missing
RNA-Seq expression. Details regarding genomic features and
data alignment of histology and genomics data are found in
the implementation details (Appendix B). Our experimental
setup is also described in the reproducibility section of our
GitHub repository.
B. Quantitative Study
TCGA-GBMLGG: Gliomas are a form of brain and spinal
cord tumors defined by both hallmark histopathological and
genomic heterogeneity in the tumor microenvironment, as well
as response-to-treatment heterogeneity in patient outcomes. The
current World Health Organization (WHO) Paradigm for glioma
classification stratifies diffuse gliomas based on morphological
and molecular characteristics: glial cell type (astrocytoma,
oligodendroglioma), IDH1 gene mutation status and 1p19q
chromosome codeletion status [59]. WHO Grading is made
by the manual interpretation of histology using pathological
determinants for malignancy (WHO Grades II, III, and IV).
These characteristics form three categories of gliomas which
have been extensively correlated with survival: 1) IDH-wildtype
astrocytomas (IDHwt ATC), 2) IDH-mutant astrocytomas
(IDHmut ATC), and 3) IDH-mutant and 1p/19q-codeleted
oligodendrogliomas (ODG). IDHwt ATCs (predominantly
WHO grades III and IV) have been shown to have the worst
patient survival outcomes, while IDHmut ATCs (mixture of
WHO Grades II, III, and IV) and ODGs (predominantly WHO
Grades II and III) have more favorable outcomes (listed in
increasing order) [59]. As a baseline against standard statistical
approaches / WHO paradigm for survival outcome prediction,
9Fig. 5: Multimodal interpretability by Pathomic Fusion in glioma. A. Local explanation of histology image, cell graph, and
genomic modalities for individual patients of three molecular subtypes. In IDHwt ATC, the network detects endothelial cells of
the microvascular proliferation in the histology image, while the cell graph localizes glial cells between the microvasculature.
In IDHmut ATC, we observe similar localization of tumor cellularity in both the histology image and cell graph, however,
attribution direction for IDH is flipped to have positive impact on survival. In ODG, we observe both modalities localizing
towards different regions containing "fried egg cells" that are canonical in ODG. For each of these patients, local explanation
reveals the most important genomic features used for prediction. B. Global explanation of top 20 genomic features for each
molecular subtype in glioma. Canonical oncogenes in glioma such as IDH, PTEN, MYC and CDKN2A are attributed highly as
being important for risk prediction.
we trained Cox Proportion Hazard Models using age, gender,
molecular subtypes and grade as covariates.
In our experimentation, we conducted an ablation study
comparing model configurations and fusion strategies in a
15-fold cross validation on two supervised learning tasks for
glioma: 1) survival outcome prediction, and 2) cancer grade
classification. For each task, we trained six different model
configurations from the combination of available modalities in
the dataset. First, we trained three different unimodal networks:
1) a CNN for in histology image input (Histology CNN), 2)
a GCN for cell graph input (Histology GCN), and 3) a SNN
for genomic features input (Genomic SNN). For cancer grade
classification, we did not use mRNA-Seq expression due to
missing data, lack of paired training examples, and because
grade is solely determined from histopathologic appearance.
After training the unimodal networks, we trained three dif-
ferent configurations of Pathomic Fusion: 1) GCN⊗SNN, 2)
CNN⊗SNN, 3) GCN⊗CNN⊗SNN. To test for ensembling,
we train multimodal networks that fused histology data with
histology data, and genomic features with genomic features.
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We compare our fusion approach to internal benchmarks and
the previous state-of-the-art [29] approach for survival outcome
prediction in glioma, which concatenates histology ROIs with
IDH1 and 1p19q genomic features. To compare with their
results, we used their identical train-test split, which was created
using a 15-fold Monte Carlo cross-validation [29].
TCGA-KIRC: Clear cell renal cell carcinoma (CCRCC) is the
most common type of renal cell carcinoma, originating from
cells in the proximal convoluted tubules. Histopathologically,
CCRCC is characterized by diverse cystic grown patterns of
cells with clear or eosinophilic cytoplasm, and a network of
thin-walled "chicken wire" vasculature [66], [67]. Genetically,
it is characterized by a chromosome 3p arm loss and mutation
status of the von Hippel-Lindau (VHL) gene, which leads to
lead to stabilization of hypoxia inducible factors that lead to ma-
lignancy [68]. Though CCRCC is well-characterized, methods
for staging CCRCC suffer from large intra-observer variability
in visual histopathological examination. The Fuhrman Grading
System for CCRCC is a nuclear grade that ranges from G1
(round or nuform nuclei with absent nucleoli) to G4 (irregular
and multilobular nuclei with prominent nucleoli). At the time of
the study, the TCGA-KIRC project used the Fuhrman Grading
System to grade CCRCC in severity from G1 to G4, however,
the grading system has received scrutiny in having poor overall
agreement amongst pathologists on external cohorts [66]. As
a baseline against standard statistical approaches, we trained
Cox Proportion Hazard Models using age, gender, and grade
as covariates.
Similar to the ablation study conducted with glioma, we
compared model configurations and fusion strategies in a 15-
fold cross validation on CCRCC, and tested for ensembling
effects. In demonstrating the effectiveness of Pathomic Fusion
in stratifying CCRCC, we use the Fuhrman Grade as a
comparative baseline in survival analysis, however, we do
not perform ablation experiments on grade classification. Since
CCRCC does not have multiple molecular subtypes, subtyping
was also not performed, however, we perform analyses on
CCRCC patient cohorts with different survival durations
(shorter surviving and longer surviving patients).
Evaluation: We evaluate our method with standard quantitative
and statistical metrics for survival outcome prediction and grade
classification. For survival analysis, we evaluate all models
using the Concordance Index (c-Index), which is defined as the
fraction of all pairs of samples whose predicted survival times
are correctly ordered among all uncensored samples (Table
I, II). On glioma and CCRCC respectively, we separate the
predicted hazards into 33-66-100 and 25-50-75-100 percentiles
as digital grades, which we compared with molecular subtyping
and grading. For significance testing of patient stratification,
we use the Log Rank Test to measure if the difference of
two survival curves is statistically significance [69]. Kaplan-
Meir estimates and predicted hazard distribution were used
to visualize how models were stratifying patients. For grade
classification, we evaluate our networks using Area Under
the Curve (AUC), Average Precision (AP), F1-Score (micro-
averaged across all classes), F1-Score (WHO Grade IV class
only), and show ROC curves (Appendix C, Fig. 7). In total,
we trained 480 models total in our ablation experiments using
TABLE I: Concordance Index of Pathomic Fusion and ablation
experiments in glioma survival prediction.
Model c-Index
Cox (Age+Gender) 0.732 ± 0.012*
Cox (Grade) 0.738 ± 0.013*
Cox (Molecular Subtype) 0.760 ± 0.011*
Cox (Grade+Molecular Subtype) 0.777 ± 0.013*
Histology CNN 0.792 ± 0.014*
Histology GCN 0.746 ± 0.023*
Genomic SNN 0.808 ± 0.014*
SCNN (Histology Only) [29]) 0.754*
GSCNN (Histology + Genomic) [29]) 0.781*
Pathomic F. (GCN⊗SNN) 0.812 ± 0.010*
Pathomic F. (CNN⊗SNN) 0.820 ± 0.009*
Pathomic F. (CNN⊗GCN⊗SNN) 0.826 ± 0.009*
*p < 0.05
TABLE II: Concordance Index of Pathomic Fusion and ablation
experiments in CCRCC survival prediction.
Model c-Index
Cox (Age+Gender) 0.630 ± 0.024*
Cox (Grade) 0.675 ± 0.036*
Histology CNN 0.671 ± 0.023*
Histology GCN 0.646 ± 0.022*
Genomic SNN 0.684 ± 0.025*
Pathomic F. (GCN⊗SNN) 0.688 ± 0.029*
Pathomic F. (CNN⊗SNN) 0.719 ± 0.031*
Pathomic F. (CNN⊗GCN⊗SNN) 0.720 ± 0.028*
*p < 0.05
15-fold cross validation. Implementation and training details
for all networks are described in detail in Appendix A and B.
V. RESULTS AND DISCUSSION
A. Pathomic Fusion Outperforms Unimodal Networks and the
WHO Paradigm
In combining histology image, cell graph, and genomic
features via Pathomic Fusion, our approach outperforms Cox
models, unimodal networks, and previous deep learning-
based feature fusion approaches on image-omic-based survival
outcome prediction (Table I, II). On glioma, Pathomic Fusion
outperforms the WHO paradigm and the previous state-of-
the-art (concatenation-based fusion [29]) with 6.31% and
5.76% improvements respectively, reaching a c-Index of 0.826.
In addition, we demonstrate that multimodal networks were
able to consistently improve upon their unimodal baselines,
with trimodal Pathomic Fusion (CNN⊗GCN⊗SNN) fusion of
image, graph, and genomic features having the largest c-Index.
Though bimodal Pathomic Fusion (CNN⊗SNN) achieved
similar performance metrics, the difference between low-to-
intermediate digital grades ([0,33) vs. [33,66) percentile of
predicted hazards) was not found to be statistically significant
(Appendix C, Table III, Fig. 9). In incorporating features from
GCNs, the p-value for testing difference in [0,33] vs. (33,66]
percentiles decreased from 0.103 to 2.68e-03. On CCRCC,
we report similar observations, with trimodal Pathomic Fusion
achieving a c-Index of 0.720 and statistical significance in
stratifying patients into low and high risk (Appendix C, Fig.
10). Using the c-Index metric, GCNs do not add significant
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Fig. 6: Multimodal interpretability by Pathomic Fusion in CCRCC. A. Local explanation of histology image, cell graph, and
genomic modalities for two longer and shorter surviving patients. In the longer surviving patient, Pathomic Fusion localizes cells
without obvious nucleoli in both the histology image and cell graph, which suggests lower-grade CCRCC and lower risk. In the
shorter surviving patient, we observe Pathomic Fusion attending to large cells with prominent nucleoli and eosinophilic-to-clear
cytoplasm in the cell graph, and the "chicken-wire" vasculature pattern in the histology image that is characteristic of higher-grade
CCRCC. Cells without clear cytoplasms are noticeably missed in both modalities for shorter survival. For each of these patients,
local explanation reveals the most important genomic features used for prediction. B. Global explanation of top 20 genomic
features for longer surviving, shorter surviving, and all patients in CCRCC. Genes such as CYP3A7, DDX43 and PITX2 are
attributed highly as being important for risk prediction, which have linked to cancer predisposition and tumor progression in
CCRCC and other cancers.
improvement over CNNs alone. However, for heterogeneous
cancers such as glioma, the integration of GCNs in Pathomic
Fusion may provide clinical benefit in distinguishing survival
curves of less aggressive tumors.
We also demonstrate that these improvements are not due
to network ensembling, as inputting same modality twice
into Pathomic Fusion resulted in overfitting (Appendix C,
Table III). On glioma grade classification, we see similar
improvement with Pathomic Fusion with increases of 2.75%
AUC, 4.23% average precision, 4.27% F1-score (micro), and
5.11% (Grade IV) over Histology CNN, which is consistent
with performance increases found in multimodal learning
literature for conventional vision tasks (Appendix C, Fig. 8,
Table V) [24].
B. Pathomic Fusion Improves Patient Stratification
To further investigate the ability of Pathomic Fusion for
improving objective image-omic-based patient stratification,
we plot Kaplan-Meier (KM) curves of our trained networks
against the WHO paradigm (which uses molecular subtyping)
on glioma (Fig. 3), and against the Fuhrman Grading System
on CCRCC (Fig. 4). Overall, we observe that Pathomic Fusion
allows for fine-grained stratification of survival curves beyond
low vs. high survival, and that these digital grades may be
useful in clinical settings in defining treatment cohorts.
On glioma, similar to [29], we observe that digital grading
(33-66 percentile) from Pathomic Fusion is similar to that of
the three defined glioma subtypes (IDHwt ATC, IDHmut ATC,
ODG) that correlate with survival. In comparing Pathomic
Fusion to Histology CNN, Pathomic Fusion was able to
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discriminate intermediate and high risk patients better than
Histology CNN. Though Pathomic Fusion was slightly worse in
defining low and intermediate risk patients, differences between
these survival curves were observed to be statistically significant
(Appendix C, Table III). Similar confusion in discriminating
low-to-intermediate risk patients is also shown in the KM
estimates of molecular subtypes, which corroborates with
known literature that WHO Grades II and III are more difficult
to distinguish than Grades III and IV [59] (Fig. 3). In analyzing
the distribution of predicted hazard scores for patients in low
vs. high surviving cohorts, we also observe that Pathomic
Fusion is able to correctly assign risk to these patients in three
high-density peaks / clusters, whereas Histology CNN alone
labels a majority of intermediate-to-high risk gliomas with low
hazard values. In inspecting the clusters elucidated by Pathomic
Fusion ([-1.0, -0.5], [1.0, 1.25] and [1.25, 1.5]), we see that
the gliomas these clusters strongly corroborate with the WHO
Paradigm for stratifying gliomas into IDHwt ATC, IDHmut
ATC, and ODG.
On CCRCC, we observe that Pathomic Fusion is able to not
only differentiate between lower and higher surviving patients,
but also assign digital grades that follow patient stratification by
the Fuhrman Grading System (Fig. 4). Unlike Histology CNN,
Pathomic Fusion is able to disentangle the survival curves
of G1-G3 CCRCCs, which have overall low-to-intermediate
survival. In analyzing the distribution of hazard predictions by
Histology CNN, we see that risk is almost uniformly predicted
across shorter and longer survival patients, which suggests that
histology alone is a poor prognostic indicator for survival in
CCRCC.
C. Multimodal Interpretability of Pathomic Fusion
In addition to improved patient stratification, we demonstrate
that our image-omic paradigm is highly interpretable, in which
we can attribute how pixel regions inhistology images, cells in
cell graphs, and features in genomic inputs are used in survival
outcome prediction.
In examining IG attributions for genomic input, we were able
to corroborate important markers such as IDH wildtype status
in glioma and CYP3A7 under-expression in CCRCC correlating
with increased risk. In glioma, our approach highlights several
signature oncogenes such as PTEN, MYC, CDKN2A, EGFR
and FGFR2, which are implicated in controlling cell cycle
and angiogenesis (Fig. 5) [70]. In examining how feature
attribution shifts when conditioning on morphological features,
several genes become more pronounced in predicting survival
across each subtype such as ANO9 and RB1 (Appendix C,
Fig. 11). ANO9 encodes for a protein that mediates diverse
physiological functions such as ion transport and phospholipid
movement across the membrane. Over-expression of ANO
proteins were found to be correlated with poor prognosis in
many tumors, which we similarly observe in our IDHmut ATC
subtype with decreased ANO9 expression decreases risk [71].
In addition, we also observe RB1 over-expression decreases risk
also in IDHmut ATC, which corroborates with known literature
that RB1 is a tumor suppressor gene. Interestingly, EGFR
amplication decreased in importance in IDHwt ATC, which may
support evidence that EGFR is not a strong therapeutic target
in glioblastoma treatment [72]. In CCRCC, Pathomic Fusion
discovers decreased CYP3A7 expression and increased PITX2,
DDX43, and XIST expression to correlate with risk, which have
been linked to cancer predisposition and tumor progression
across many cancers (Fig. 6) [73]–[77]. In conditioning on
morphological features, HAGHL, MMP1 and ARRP21 gene
expression becomes more highly attributed in risk prediction
(Appendix C, Fig 11) [78], [79]. For cancers such as CCRCC
that do not have multiple molecular subtypes, Pathomic Fusion
has the potential to refine gene signatures in cancers, and
uncover new prognostic biomarkers that can be targeted in
therapeutic treatments.
Across all histology images and cell graphs in both organ
types, we observe that Pathomic Fusion broadly localizes both
vasculature and cell atypia as an important feature in survival
outcome prediction. In ATCs, Pathomic Fusion is able to
localize not only regions of tumor cellularity and microvascular
proliferation in the histology image, but also glial cells between
the microvasculature as depicted in the cell graph (Fig. 5). In
ODG, both modalities attend towards "fried egg cells", which
are mildly enlarged round cells with dark nuclei and clear
cytoplasm characteristic in ODG. In CCRCC, Pathomic Fusion
attends towards cells with indiscernible nucleoli in longer
surviving patients, and large cells with clear nucleoli in shorter
surviving patients that is indicative of CCRCC malignancy (Fig.
6). An important aspect about our method is that we are able to
leverage heatmaps from both histology images and cell graphs
to explain prognostic histological features used for prediction.
Though visual explanations from the image and cell graph
heatmap often overlap in localizing cell atypia, the cell graph
can be used to uncover salient regions that are not recognized in
the histology image for risk prediction. Moreover, cell graphs
may have additional clinical potential in explainability, as the
attributions refer to specific atypical cells rather than pixel
regions.
VI. CONCLUSION
The recent advancements made in imaging and sequencing
technologies is transforming our understanding of molecular
biology and medicine with multimodal data. Next-generation
sequencing technologies such as RNA-Seq is redefining clinical
grading paradigms to include bulk quantitative measurements
from molecular subtyping [59]. Tangential to this growth field
has been the emergence of tissue imaging instrumentation such
as whole-slide imaging, which capture the organization of cells
and their surrounding tissue architecture. In this work, we
present Pathomic Fusion, a novel framework for integrating
data from these technologies for building objective image-
omic assays for cancer diagnosis and prognosis. We extract
morphological features from histology images using CNNs
and GCNs and genomic features using SNNs and fuse these
deep features using the Kronecker Product and a gating-based
attention mechanism. We validate our approach on glioma and
CCRCC data from TCGA, and demonstrate how multimodal
networks in medicine can be used for fine-grained patient
stratification and interpretted for finding prognostic features.
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The method presented is scalable and interpretable for multiple
modalities of different data types, and may be used for inte-
grating any combination of imaging and multi-omic data. The
paradigm is general and may be used for predicting response
and resistance to treatment. Multimodal interpretability has the
ability to identify new and novel integrative bio-markers of
diagnostic, prognostic and therapeutic relevance.
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APPENDIX A. DEEP LEARNING-BASED SURVIVAL ANALYSIS
Survival analysis is a task that models the time to an event, where the outcome of the event is not always observed. Such
events are called censored, in which the date of the last known encounter is used as a lower bound of the survival time. For the
task of cancer survival outcome prediction, an uncensored event would be patient death, and a censored event would include
either patient survival or last known follow-up.
Let T be a continuous random variable that represents patient survival time, and the survival function S(t) = P (T ≥ t0) be
the probability of a patient surviving longer than time t0. We can denote the probability that an event occurs instantaneously at
a time t (after t0) as the hazard function λ(t). Integrating the hazard function over the time between t and t0 gives us the
survival function [80].
λ(t) = lim
∂t→0
P (t ≤ T ≤ t+ ∂t|T ≥ t)
∂t
, S(t) = exp
(
−
∫ t
0
λ(x)∂x
)
.
The most common semi-parametric approach for estimating the hazard function is the Cox proportion hazards model, which
assumes that the hazard function can be parameterized as an exponential linear function λ(t|x) = λ0(t)eβx, where λ0(t) is
the baseline hazard that describes how the risk of an event changes over time, β are model parameters that describe how the
hazard varies with covariates / features X of a patient. In the original model, the baseline hazard λ0(t) is left unspecified,
making it difficult to estimate β, however, the Cox partial log-likelihood can be derived that expresses the likelihood of an
event to be observed at time t for β,X [81].
l(β,X) = −
∑
i∈U
Xiβ − log ∑
j⊂Ri
eXjβ
 , ∂l(β,X)
∂Xi
= δ(i)β −
∑
i,j∈Cj ,U
βeXiβ∑
k∈Cj e
Xkβ
where U is the set of uncensored patients, Ri is the set of patients whose time of death or last follow-up is later than
i. From the partial log-likelihood, β can be estimated using iterative optimization algorithms such as Newton-Raphson or
Stochastic Gradient Descent. To train deep networks for survival analysis, features from the hidden layer are used as covariates
in the Cox model, with the derivative of the partial log-likelihood used as error during back-propagation. To evaluate the
performance of networks for survival analysis, we use the Concordance Index (c-Index), which measures the concordance of
ranking of predicted hazard scores with the ground truth survival times of patients. To demonstrate how well Pathomic Fusion
performs over other models, we used the c-Index as a comparative performance metric to measure how well each model is
able to predict hazard scores amongst patients (higher is better). Our baseline for clinical practice was using the ground truth
molecular subtypes as covariates in a Cox proportional hazard model - the canonical regression technique for modeling survival
distributions. P-Values were calculated using the Log Rank Test, which we used to assess low vs. high risk stratification on all
datasets, low vs. intermediate and intermediate vs. high (33-66-100 percentile) risk stratification in glioma, and 25-50-75-100
percentile risk stratification in CCRCC [69].
APPENDIX B. IMPLEMENTATION DETAILS
A. Inclusion Criteria for Genomic and Transcriptomic Features
Fig. 7: Missing data in the TCGA-GBMLGG project.
Because not all genomic features are available for all
patients, Pathomic Fusion was trained with different
subsets of the data than the unimodal networks for both
survival outcome prediction and grade classification.
In our analysis on the merged TCGA-GBMLGG and TCGA-KIRC
projects, we use 320 and 357 genomic features respectively. Genomic
features include mutation (e.g. - binary indication of mutation status
for IDH1 gene, 0/1) and copy number variation (CNV) (e.g. -
amplified / deleted copies for genes and chromosomal regions). Copy
number variation measurement in TCGA uses the Affymetrix SNP
6.0 array to identify repeated copies of genomic regions, with the
final output as segment mean values (amplified regions have positive
values, deleted regions have negative values). For TCGA-GBMLGG,
mutation and CNV data used in our analysis were curated from the
same set of genomic features used in Mobadersany et al. [29]. Genes
curated include EGFR, MDM4, MGMT, MYC and BRAF, which are
implicated in oncogenic processes such as angiogenesis, apoptosis,
cell growth, and differentiation. For TCGA-KIRC, we used the most
amplified /deleted genes (all CNVs with greater than 7% amplification
or deletion), which yielded 117 CNV features. For both projects, we
included RNA-Seq expression, which is measured as the quantified
bulk abundance of mRNA transcripts. Using cBioPortal, we selected
the top 240 differentially expressed genes for both projects [65].
Because our genomic features do not share any explicit spatial or temporal dependencies with each other, we feed our features
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through a Self-Normalizing Feedforward Network to learn a low-dimensional representation before fusing it with histology and
cell graph modalities.
B. Data Missingness and Alignment in TCGA-GBMLGG
To draw comparisons with the previous state-of-the-art, we used the existing curated TCGA-GBMLGG data found in the
supplement of [29], which required in careful handling of missing values in multimodal data. For each patient, 1-3 20x
1024× 1024 histology ROIs (0.5 µ / pixel) from diagnostic slides, and 320 genomic features were used. Of the 769 patients,
72 patients have missing molecular subtype (IDH mutation and 1p19q codeletion), 33 patients have missing histological
subtype and grade labels, and 256 patients have missing mRNA-Seq data (Fig. 6). Because multiple ROIs from diagnostic
slides were obtained for some patients, each image was treated as a single data point in cross-validation, with the genomic and
ground-truth label information copied over. A 15-fold Monte-carlo cross-validation was conducted using the same train-test
splits as the supplement of [29], which were generated randomly with 80% training and 20% testing (split by TCGA ID).
Depending on the task (survival prediction vs. grade classification) and combination of modalities used (histology vs. genomic
vs. histology+genomic), different subsets of the train split were used to train the unimodal and multimodal networks due to
missingness. In validating our models on the test splits of the cross-validation with missing data, test splits were standardized
to exclude all missing data across all models (center overlap in Figure 5.). Data missingness was not an issue in working with
CCRCC, with all unimodal and multimodal networks trained with the same train-test splits in a 15-fold cross-validation.
C. Network Architectures
Three different network architectures were used to process the three modalities in our problem: 1) a VGG19 CNN with
batch normalization for histology images, 2) a GCN for cell spatial graphs, and 3) a Feedforward Self-Normalizing Network
for molecular profiles. The VGG19 network consists of 16 convolutional, 3 fully connected and 5 max pooling layers, with 512
× 512 sized images used as input. Dropout probabilities of 0.25 were applied after the first two fully connected layers (of size
1024), with a mild dropout (p=0.05) applied after the last hidden layer (of size 32). Our GCN consisted of 3 GraphSAGE
and Self-Attention Pooling layers with hidden dimension 128, followed by two linear layers of size 128 and 32. Lastly, our
Genomic SNN consists of 4 consecutive blocks of fully-connected layers with dimensions [64, 48, 32, 32], ELU activation, and
Alpha Dropout. For survival outcome prediction, all networks were activated using the Sigmoid function, with the output scaled
to be between -3 and 3. For grade classification, all networks were activated using the Log Softmax to compute scores for each
of the 3 WHO Grades.
Our multimodal network architectures consist of two components: 1) Gating-based Modality Attention, and 2) fusion by
Kronecker Product. Each modality was gated using three linear layers, with the second linear layer used to compute the attention
scores. For survival outcome prediction, the genomic modality was used to gate over the image and graph modalities, while for
grade classification, the histology image modality was used to gate over the genomic and graph modality. Additional dimension
reduction of the gated unimodal feature representations was performed to reduce the output size of the Kronecker product
feature space in the trimodal network. In our trimodal network, for survival outcome prediction, the first and third linear layers
for the genomic modality have 32 hidden units to maintain the feature map dimension, with the linear layers in the image and
graph modalities having 16 hidden units in order to transform the feature representations into a lower dimension. For grade
classification, we maintained the feature dimension of our histology image modality instead, and reduced the dimension of
the graph and genomic modalities. No feature dimension reduction was done in bimodal networks in any tasks. For feature
fusion, the Kronecker product of the respective unimodal feature representations for each modality was computed, creating
feature maps of size: [33× 33], [33× 33], [33× 17× 17] for our CNN⊗SNN, GCN⊗SNN, and CNN⊗GCN⊗SNN. To use the
unperturbed unimodal features, we appended 1 to each feature vector before computing the Kronecker Product. Dropout layers
with probability (p = 0.25) were inserted after gating and computing the multimodal tensor.
D. Experimental Details
Pathomic Fusion was built with PyTorch 1.5.0, PyTorch Geometric 1.5.0, Captum 0.2.0, and Lifelines 0.24.6. Node features
for cell graph construction were calculated by: 1) segmenting each nuclei, 2) using the Contours Features Toolbox in in
OpenCV 4.2.0, 3) the Texture Feature Toolbox in , 4) self-supervised deep features using Contrastive Predictive Coding, and 5)
PyFlann 1.6.14 for graph construction. Resources used in our experimentation include 12 Nvidia GeForce RTX 2080 Tis on
local workstations, and 2 Nvidia Tesla V100s on Google Cloud. The Histology CNN was initialized using pretrained weights
from ImageNet, followed by finetuning the network using a low learning rate of 0.0005 and a batch size of 8. Random crops
of 512 × 512, color jittering, and random vertical and horizontal flips were performed of data augmentation. The Histology
GCN and Genomic SNN were initialized using the self-normalizing weights from Klambeur et al. [58], and trained with a
learning rate of 0.002 with a batch size of 32 and 64 respectively. For the Genomic SNN, a mild L1 regularization was also
used with hyperparameter value 3e-4 to enforce feature sparsity. All networks were trained with the same epochs using the
Adam optimizer, dropout probability p = 0.25, and a linearly decaying learning rate scheduler.
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After training the Histology CNN, for each 1024× 1024 histology ROI, we extract [32× 1] embeddings from 9 overlapping
512× 512 patches, which we pair with their respective cell graph and genomic feature input as input into Pathomic Fusion. For
the Histology GCN and Genomic SNN, we first trained their respective unimodal networks with the aforementioned training
details, and then trained the last linear layers of the multimodal network with the unimodal network modules frozen with
a learning rate of 0.0001 and Adam solver. At epoch 5, we unfroze the genomic and graph networks, and then trained the
network for 25 more epochs using a learning rate of 0.0001, Adam solver, and a linearly decaying learning rate scheduler.
E. Evaluation Details
The predicted hazard and grade scores from each unimodal and multimodal network were evaluated on the test splits of
the 15-fold cross-validation. To use the entire 1024× 1024 histology image for CNN-based survival outcome prediction on
TCGA-GBMLGG, similar to previous work, we computed the mean of hazard predictions from 9 overlapping 512 × 512
image crops across all histology ROIs belonging to each patient. For plotting the Kaplan-Meier curves, we pooled predicted
hazards from all of the test splits in the 15-fold cross-validation and plotted them against their survival time. For creating the
Swarm plots, we z-scored predicted hazards in each split before pooling so that scores for low vs. intermediate risk would
have similar ranges in visualization. For grade classification on TCGA-GBMLGG, we used the max softmax activation score
from overlapping 512× 512 patches to determine class. For CNN-based survival outcome prediction on CCRCC, we similar
computed the mean of hazard predictions from 512× 512 histology ROIs for each patient.
APPENDIX C. ABLATION STUDIES AND COMPARATIVE ANALYSIS
TABLE III: Concordance Index & statistical significance of Pathomic Fusion and ablation experiments in glioma survival
prediction.
Model c-Index ↑ [0,50] vs. (50,100] ↓ [0,33] vs. (33,66] ↓ [33,66] vs. (66,100] ↓
Cox (Age+Gender) 0.732 ± 0.012* 1.90e-92 1.48e-38 5.93e-27
Cox (Grade) 0.738 ± 0.013* 6.00e-255 9.57e-23 2.94e-66
Cox (Molecular Subtype) 0.760 ± 0.011* 2.07e-228 4.65e-26 1.45e-51
Cox (Grade+Molecular Subtype) 0.777 ± 0.013* 5.29e-215 1.14e-40 5.02e-52
Histology CNN 0.792 ± 0.014* 5.09e-40 1.77e-07 6.61e-25
Histology GCN 0.746 ± 0.022* 1.62e-21 2.29e-03 4.20e-15
Genomic SNN 0.808 ± 0.014 1.52e-52 0.153 2.16e-81
SCNN (Histology Only) [29]) 0.754* 2.08e-61 - -
GSCNN (Histology+Genomic) [29]) 0.781* 3.08e-64 - -
Pathomic F. (GCN⊗SNN) 0.812 ± 0.010* 1.06e-55 0.209 3.09e-80
Pathomic F. (CNN⊗SNN) 0.820 ± 0.009* 5.18e-57 0.103 4.56e-79
Pathomic F. (CNN⊗GCN⊗SNN) 0.826 ± 0.009* 7.09e-57 2.68e-03 5.82e-74
**p < 0.05
TABLE IV: Concordance Index & statistical significance of Pathomic Fusion and ablation experiments in CCRCC survival
prediction.
Model c-Index ↑ [0,50] vs. (50,100] ↓ [0,25] vs. (25,50] ↓ [25,50] vs. (50,75] ↓ [50,75] vs. (75,100] ↓
Cox (Age+Gender) 0.630 ± 0.024* 1.27e-16 0.108 1.2e-05 0.360
Cox (Grade) 0.675 ± 0.036* 4.42e-17 1.25e-07 4.52e-04 0.513
Histology CNN 0.671 ± 0.023* 3.87e-16 0.481 1.74e-04 4.19e-04
Histology GCN 0.648 ± 0.031* 4.23e-02 0.012 0.651 0.144
Genomic SNN 0.685 ± 0.024* 8.84e-19 0.480 0.013 7.07e-16
Pathomic F. (GCN⊗SNN) 0.688 ± 0.029* 1.65e-17 0.301 0.069 1.79e-12
Pathomic F. (CNN⊗SNN) 0.719 ± 0.031* 1.11e-27 0.772 7.00e-6 5.77e-12
Pathomic F. (CNN⊗GCN⊗SNN) 0.720 ± 0.028* 2.48e-24 0.087 9.37e-3 1.08e-14
**p < 0.05
F. Ensembling Effects
In order to further validate the performance improvement in multimodal networks presented in Table I we conduct ensambling
experiments. In other words, for a fair comparison we compare the performance of our multimodal networks against CNN⊗CNN,
GCN⊗GCN and SNN⊗SNN in order to rule out ensembling effects causing the observed improvement. Table II summarizes
these results and we demonstrate that the improvement from Pathomic Fusion is greater than fusing the same modality using
the same architecture.
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Fig. 8: Comparative analysis of AUC curves for Histology CNN and Pathomic Fusion in grade classification. The confidence
interval is representative of the 15-fold cross validation. Since grade is usually determined via histology, our Genomic SNN
that uses only CNV, gene mutation and chromosome deletion is not predictive of grade. Pathomic Fusion has greater AUCs
in all cases, and performs particularly well on grade IV potentially because IDH mutation and 1p19q co-deletion from the
genomic profile aid in discriminating Grade IV astrocytomas and Grade II/III oligodendrogliomas.
TABLE V: Comparative analysis of the ensembling effects of unimodal networks. Overall, ensemble models of Histology
CNN, Histology GCN, and Genomic SNN caused networks to overfit and decrease in performance. Improvements made by
ensembling were marginal compared to improvements made by Pathomic Fusion.
Model c-Index ↑ AUC ↑ AP ↑ F1-Score (Micro) ↑ F1-Score (Grade IV) c-Index ↑
Histology CNN 0.750 ± 0.010 0.883 ± 0.008 0.793 ± 0.017 0.717 ± 0.017 0.873 ± 0.013 0.671 ± 0.023
Histology (CNN + CNN) 0.749 ± 0.010 0.888 ± 0.007 0.807 ± 0.013 0.715 ± 0.021 0.879 ± 0.015 0.671 ± 0.023
Histology GCN 0.722 ± 0.014 0.849 ± 0.011 0.764 ± 0.012 0.665 ± 0.019 0.849 ± 0.011 0.648 ± 0.031
Histology (GCN + GCN) 0.720 ± 0.014 0.851 ± 0.015 0.763 ± 0.021 0.650 ± 0.023 0.812 ± 0.022 0.643 ± 0.027
Genomic SNN 0.808 ± 0.014 0.853 ± 0.012 0.729 ± 0.018 0.652 ± 0.015 0.857 ± 0.017 0.684 ± 0.025
Genomic (SNN + SNN) 0.794 ± 0.014 0.850 ± 0.012 0.725 ± 0.019 0.651 ± 0.018 0.856 ± 0.017 0.684 ± 0.025
Pathomic F. (GCN⊗SNN) 0.812 ± 0.010 0.897 ± 0.010 0.812 ± 0.016 0.714 ± 0.018 0.902 ± 0.014 0.686 ± 0.024
Pathomic F. (CNN⊗SNN) 0.820 ± 0.009 0.905 ± 0.010 0.833 ± 0.016 0.730 ± 0.019 0.913 ± 0.011 0.719 ± 0.031
Pathomic F. (CNN⊗GCN⊗SNN) 0.826 ± 0.009 0.908 ± 0.008 0.828 ± 0.016 0.749 ± 0.020 0.920 ± 0.014 0.720 ± 0.028
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Fig. 9: A. TCGA-GBMLGG Kaplan-Meier comparative analysis of Histology CNN, Histology GCN, Genomic SNN, and
Pathomic Fusion with respect to IDHwt ATCs, IDHmut ATCs, ODGs, and all molecular subtypes in stratifying WHO Grades II,
III, and IV using the 33-66-100 percentile of hazard predictions. Overall, we observe that this heuristic has similar stratification
of patients as the WHO grading system, with Pathomic Fusion having the closest resemblance. B. Distribution of hazard
predictions for Histology CNN, Histology GCN, Genomic SNN, and Pathomic Fusion. Histology CNN and Histology had
similar skewed distributions of hazard. Qualitatively, the distribution of hazard predictions by Genomic SNN is divided into
clusters, while Pathomic Fusion produced is able to delineate three clusters.
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Fig. 10: A. CCRCC Kaplan-Meier comparative analysis of Histology CNN, Histology GCN, Genomic SNN, and Pathomic
Fusion in stratifying low vs. high survival using the 50-100 percentile of hazard predictions, and Fuhrman Grades I, II, III, and
IV using the 25-50-75-100 percentile of hazard predictions. In performing fine-grained stratification with four risk categories,
Pathomic Fusion performed the best in disentangling each category. B. Distribution of hazard predictions for Histology CNN,
Histology GCN, Genomic SNN, and Pathomic Fusion.
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Fig. 11: Genomic SNN and Pathomic Fusion global explanation across patient cohorts in TCGA-GBMLGG and CCRCC.
Attribution color corresponds to low (blue) vs. high (red) feature value, and attribution direction corresponds to how the gene
feature value contributes to low risk (left) vs. high risk (right). Data points in the summary plots correspond to local explanations
made by Integrated Gradients when attributing features for a given sample. Top 20 features were ranked by mean absolute
attribution. A. Global explanation for each molecular subtype in TCGA-GBMLGG. OBSCN, FAT4, HRNR, RPL5, RBBP6,
RB1, and ANO9, FAM47A feature importance increased when conditioned on morphological features, while EGFR feature
importance decreased. B. Global explanation for longer surviving, shorter surviving, and all patients in TCGA-KIRC. Longer
and shorter surviving patient cohorts were defined by the top 25 longest and shortest surviving patients respectively. MMP1,
HAGHL, and ARRP21 feature importance increased when conditioned on morphological features.
